Chemotargets is a leading biotech in the new field of precision modeling. We use our state-of-the-art computational approaches to predict the off-target pharmacology and anticipate the safety profile of small molecules within the context of the human system. Following current trends in precision medicine, the company is strategically positioned to address challenges in this field by incorporating the impact of personal metabolomic variations. Our software is currently license by a wide range of customers, including top-10 pharma, small- and mid-sized biotechs, and academic institutions.

  • Area de Negocio
  • Desarrollo de software
  • Bioinformática
  • Tipo de Empresa
  • Servicios tecnológicos
Doctor Aiguader, 88 - Parc de Recerca Biomèdica de Barcelona
Barcelona, Barcelona 08003, ES

Dr. Jordi Mestres, CEO

Our CT-link software allows to connect small molecules, protein targets, safety events, organs, and diseases, all in the context of the endogenous human metabolome, providing a truly advanced precision modeling framework. Navigation on these interlinked big data is facilitated by an easy-to-use Graphical User Interface designed to be used by chemists, pharmacologists, toxicologists, and managers alike.

In terms of services, we have been involved in numerous contract research services with the entire spectrum of companies interested in this field: from big and medium pharmaceutical companies, to small biotech's, to chemical companies interested in purposely designed chemical libraries.

Our technologies allow for designing portfolio-driven screening collections, identify the mechanism of action of phenotypically-active molecules, generate metabolites, anticipate adverse events much earlier in the drug discovery process, and identify potential repurposing opportunities.

Collaborations and Clients

In the last few years, the company has strategically moved from being mainly a service company (earning its revenues from the outsourcing of drug discovery programs) to becoming a main player in offering a cutting edge computational platform in the field of precision modeling (earning now our revenues from the licensing of our software).

We have also been involved in two EU projects: eTOX, an IMI-JU project to develop predicting models of preclinical drug safety, and MICROSMETICS, a Marie Curie action project to identify novel small molecules from microorganisms that could be used in cosmetics.

Our current client portfolio includes several of the top-25 pharma companies, biotechs, and academic institutions active in the field of drug discovery. But we are actively looking at expanding our portfolio to agrochemical and cosmetic companies, since we believe they could truly benefit from our software.

We are also seeking at present partnering/collaborations with companies in the field that could be complementary to ours, with particular focus on database companies that provide additional data to feed our models.